Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction
Kurzfassung: Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reductionalirocumab monotherapy reduced "bad cholesterol three t ...
[Sanofi-Aventis - 16.10.2013] Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction
alirocumab monotherapy reduced "bad cholesterol three times more than ezetimibe
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), met its primary efficacy endpoint. The mean low-density lipoprotein-cholesterol (LDL-C, or "bad cholesterol) reduction from baseline to week 24, the primary efficacy endpoint of the study, was significantly greater in patients randomized to alirocumab, as compared to patients randomized to ezetimibe (47.2% vs. 15.6%, p
Weitere Informationen
Sanofi-Aventis
Weitere Informationen finden sich auf unserer Homepage
Sanofi-Aventis,
, 65926 Frankfurt am Main , Deutschland
Tel.: ;
Weitere Meldungen dieses Unternehmens
Die Pressemeldung "Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction" unterliegt dem Urheberrecht.
Jegliche Verwendung dieses Textes, auch auszugsweise, erfordert die vorherige schriftliche Erlaubnis des Autors.
Autor der Pressemeldung "Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction" ist Sanofi-Aventis, vertreten durch .